CS
TCRX icon

Credit Suisse’s TScan Therapeutics TCRX Stock Holding History

Credit Suisse’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$138K Buy
+17,366
New +$109K ﹤0.01% 2921

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Credit Suisse's TCRX Position: Q1 2024 in Review

Credit Suisse opened a new position in TScan Therapeutics (TCRX) in Q1 2024: 17,366 shares worth $138K. The stake represents ﹤0.01% of the portfolio and ranks #2921 among its holdings.

66 funds tracked by Wall St. Rank hold TCRX as of Q1 2024.

  • Credit Suisse held 17,366 shares of TScan Therapeutics worth $138K as of Q1 2024.
  • TScan Therapeutics was a new Credit Suisse position in Q1 2024.
  • TScan Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2921 holding.
  • 66 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.